Sep 11 2026 09:03 PM EST

Cooper Companies Shares Slide as Inventory Actions and Strategic Decisions Weigh on Outlook

Shares of The Cooper Companies, Inc. (NASDAQ: COO) fell sharply this week after the company’s third-quarter results and the board’s decision to retain its CooperSurgical unit prompted investors to reassess the near-term outlook. The stock dropped 22.2% over the past five days, with a particularly steep 14.7% decline following the earnings release, as guidance cuts, continued inventory reductions at CooperVision and perceived strategic uncertainty overshadowed otherwise strong free cash flow and expanded share buybacks.

The immediate catalyst for the selloff was the company’s fiscal third-quarter report and forward guidance. Revenue for the quarter rose 1% year-over-year to $1.066 billion, missing analyst expectations. Non-GAAP earnings per share of $1.15 beat consensus by 3.6%, helped by productivity gains, but management cut the full-year revenue outlook for the fourth time in two years to a midpoint of $4.24 billion. The updated forecast, along with confirmation that the CooperSurgical unit would not be sold, led to a wave of analyst downgrades and a 22.2% five-day slide in the stock.

Inventory Destocking and Segment Pressures

The principal operational headwind remains aggressive inventory reductions at CooperVision, the company’s contact lens business. Proactive U.S. channel destocking depressed reported revenue in the Americas, even as underlying demand trends stayed healthy. Without the inventory action, Americas segment revenue would have grown around 5% for the quarter; instead, CooperVision sales were flat year-over-year at $717 million, and overall organic growth was limited to 1%.

The company indicated these inventory actions will persist into the fourth quarter but expects the impact to normalize by fiscal 2027. Meanwhile, CooperSurgical delivered $349 million in revenue, up 3% organically, with fertility products growing 5%. However, the segment continues to face mixed results internationally, with macroeconomic and geopolitical headwinds weighing on performance, particularly in Asia-Pacific and the Middle East.

Strategic Review Outcome and Market Response

Investor expectations around the board’s strategic review had centered on a potential divestiture of CooperSurgical to unlock value. The board’s decision to retain the unit—citing temporary valuation disconnects from new competitive entrants and litigation settlements—was met with disappointment by some investors and analysts. While the company expanded its share repurchase authorization to $3 billion and added two independent directors, these actions were insufficient to offset concerns about the growth trajectory and asset value.

Analyst downgrades followed, with William Blair moving COO to Market Perform from Outperform. Price targets were revised downward across the sell side, and sentiment turned more cautious as guidance cuts and ongoing operational headwinds were seen as likely to persist into the end of the year.

Financial Position, Cash Flow and Guidance

Despite the top-line disappointment, Cooper Companies reported record quarterly free cash flow of $273 million and raised its full-year cash flow outlook to $650 million. The company’s net income for the quarter was $432.8 million, bolstered by a $307 million discrete tax benefit related to a favorable UK tax resolution.

For the fourth quarter, Cooper Companies projects revenue of $1.057–$1.08 billion and adjusted EPS of $1.05–$1.09, reflecting flat to 2% organic growth and margin pressures from increased commercial investment, foreign exchange headwinds, and lower tariff refunds. The company expects a higher effective tax rate in 2027 as U.S. GILTI rules phase in.

Competitive and Sector Dynamics

CooperVision continues to face intense competition from Alcon, Johnson & Johnson Vision, and Bausch + Lomb, particularly in the premium daily, toric, and myopia management lens categories. Legacy hydrogel products are being phased out, which has weighed on short-term growth, while newer offerings such as MyDay and MiSight have shown double-digit growth. The company is investing in salesforce expansion and marketing to support a broader product rollout in the U.S. and Europe, aiming to restore growth rates to market levels in 2027.

The fertility and women’s health business remains solid in the Americas, but results in EMEA and Asia-Pacific have been uneven amid supply chain disruptions, inflation, and regulatory shifts. Macroeconomic volatility, including rising labor and supply costs, has added to sector margin pressure, with medical groups reporting average operating cost increases of 11% year-to-date.

Risks and Investor Considerations

The market’s reassessment of Cooper Companies reflects persistent uncertainty over the pace of recovery in its core segments, the ability to execute on commercial investments, and the resolution of litigation and recall risks. The board’s decision to retain CooperSurgical, rather than pursue a sale, has left questions about long-term strategy and capital allocation. While the company’s balance sheet and cash generation remain robust, near-term earnings growth is likely to be constrained by inventory normalization, margin pressure, and sector-wide cost inflation.

The shares now trade at a forward P/E of 35.66, with a median analyst price target of $83.19 but recent targets as low as $66. Market attention is likely to remain focused on the pace of inventory recovery, effectiveness of commercial investments, and whether Cooper Companies can deliver on its long-term growth and margin ambitions in a more challenging sector landscape.